Chimeric Therapeutics (ASX: CHM)

Last close As at 02/07/2024

0.04

0.00 (0.00%)

Market capitalisation

22m

Latest Insights

Balance Sheet

Forecast net cash (A$m)

8.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (47.4) (45.9) (66.7)
Relative (46.7) (45.2) (67.3)
52 week high/low A$0.2/A$0.0

Financials

Edison Investment Research is terminating coverage on Chimeric Therapeutics (CHM). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021A 0.0 (14.8) (14.9) (8.16) N/A N/A
2022E 0.0 (14.0) (14.0) (4.19) N/A N/A
2023E 0.0 (14.5) (14.5) (4.32) N/A N/A

Thematics

thematic

Investment Companies

Emerging markets – Worthy of consideration

thematic

Investment Companies

Dynam Capital at the 2024 Vietnam ESG Conference

thematic

TMT

MediaWatch – Glimpses of positivity

thematic

Consumer

ConsumerWatch – Give me a reason to love you

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free